Our Executive Director will moderate a thought-provoking session during the 2025 Prevent Cancer Dialogue Virtual Series on October 8, 2025.

The panel, titled Molecular Residual Disease (MRD): Exploring the Impact on Cancer Early Detection and Personalized Care, will feature:

• Heather Parsons, M.D., MPH – Fred Hutchinson Cancer Center

• Amir Jazaeri, M.D. – Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center

• Jeff Gregg, M.D. – Foresight Diagnostics

This session will highlight the rapidly evolving science of MRD testing, a groundbreaking approach that is reshaping cancer detection and treatment strategies. Panelists will discuss the origins of MRD in clinical medicine, the evidence supporting its use today, and the opportunities it presents for future research and application.

Attendees will gain insights into how MRD testing can help predict relapse risk, detect recurrence at its earliest stages, and guide more personalized treatment decisions—ultimately improving patient outcomes.